3B) and in the hippocampus (F(3–16) = 1.693; p = 0.20; Fig. 2A), there were no alterations in the BDNF levels after chronic treatment. The acute treatment did not alter the NGF protein levels in the prefrontal cortex (F(3–16) = 1.024; p = 0.40 Fig. 2B), in the amygdala (F(3–16) = 3.076; p = 0.58 Fig. 2B) or in the hippocampus (F(3–16) = 0.095; p = 0.96 Fig. 2B). The

chronic treatment increased the NGF levels in the prefrontal cortex with lamotrigine at the dose of 10 and 20 mg/kg (F(3–15) = 8.982; p = 0.01 Fig. 2B), compared with saline, but the NGF protein levels did not alter in the prefrontal cortex with imipramine at the dose of 30 mg/kg (F(3–15) = 8.982; p = 0.57 Fig. 2B). The amygdala (F(3–16) = 0,230; p = 0.87 Fig. 2B) and the hippocampus Entinostat ic50 (F(3–16) = 3.2080; p = 0.51 Fig. 2B) did not have alterations in the BDNF levels after chronic treatment. The acute treatment increased the citrate synthase activity in the amygdala with imipramine at the dose of 30 mg/kg (F(3–10) = 6.474; p = 0.02

Fig. 3A) compared with saline. In the prefrontal cortex and hippocampus there were no alterations in the citrate synthase activity after acute treatment. The chronic treatment did not alter the citrate synthase activity in the prefrontal cortex (F(3–11) = 0.460; p = 0.71 Fig. 3A), amygdala (F(3–12) = 2.676; p = 0.94 Fig. 3A) or hippocampus (F(3–12) = 3.079; SB431542 in vivo p = 0.68 Fig. 3A). The acute treatment increased the creatine kinase activity in the amygdala with imipramine at the dose

of 30 mg/kg (F(3–15) = 5.415; p = 0.01 Fig. 3B), compared with saline. The chronic treatment increased the creatine kinase activity in the hippocampus Dichloromethane dehalogenase with imipramine at the dose of 30 mg/kg and lamotrigine at the dose of 10 mg/kg (F(3–15) = 7.967; p = 0.02 Fig. 3B), compared with control group. The acute treatment decreased the mitochondrial complex I activity in the prefrontal cortex with imipramine at the dose of 30 mg/kg and lamotrigine at the dose of 10 mg/kg (F(3–14) = 10.859; p < 0.001 Fig. 4A) compared with control group. The chronic treatment did not alter the mitochondrial complex I activity in the prefrontal cortex (F(3–14) = 0.570; p = 0.64 Fig. 4A), amygdala (F(3–14) = 2.599; p = 0.09 Fig. 4A) or hippocampus (F(3–12) = 0.875; p = 0.48 Fig. 4A). The acute administration increased the mitochondrial complex II activity in the amygdala with imipramine at the dose of 30 mg/kg and lamotrigine at the dose of 20 mg/kg (F(3–13) = 21.798; p < 0.001 Fig. 4B), and in the hippocampus with lamotrigine at the dose of 10 mg/kg (F(3–11) = 5.643; p = 0,02 Fig. 4B) compared with saline. The chronic treatment increased the mitochondrial complex II activity in the prefrontal cortex (F(3–15) = 19.218; p < 0,001 Fig. 4B) and hippocampus (F(3–12) = 4.471; p = 0,03 Fig.